02:08 , Jul 26, 2017 |  BC Extra  |  Company News

Lilly stretches Olumiant timeline, updates cancer strategy

Eli Lilly and Co. (NYSE:LLY) reported 2Q17 earnings and said it would delay its plans to resubmit an NDA for Olumiant baricitinib beyond 2017. The company also said it would narrow its oncology focus to...
20:31 , Apr 21, 2017 |  BC Week In Review  |  Company News

Respira, United Therapeutics deal

Respira granted United Therapeutics exclusive, North American rights to RT234 to treat pulmonary hypertension. United Therapeutics will provide funding to Respira to develop RT234 through approval and United Therapeutics will be responsible for commercialization. The...
23:48 , Feb 28, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cell-free assays A synaptosome-based assay of long-term synaptic potentiation could be used to screen therapies to treat AD. The assay involved isolating synaptosomes from frozen, postmortem parietal cortex samples from AD patients and unaffected...
22:48 , Feb 8, 2017 |  BC Week In Review  |  Clinical News

Tadalafil PharmFilm regulatory update

MonoSol said FDA accepted for review an NDA for Tadalafil Oral Soluble Film (OSF) to treat erectile dysfunction (ED). The PDUFA date is Sept. 18. The product is a film formulation of tadalafil, a phosphodiesterase-5...
01:44 , Dec 30, 2016 |  BC Week In Review  |  Company News

Lilly joins cTAP consortium

The Collaborative Trajectory Analysis Project (cTAP) said Eli Lilly has joined the consortium. The group, which includes scientists, drug companies, patient advocacy organizations and clinical centers, is collaborating to advance treatments for Duchenne muscular dystrophy...
00:10 , Dec 22, 2016 |  BC Extra  |  Company News

Lilly joins DMD consortium

The Collaborative Trajectory Analysis Project (cTAP) said Eli Lilly and Co. (NYSE:LLY) has joined the consortium. The group, which includes scientists, drug companies, patient advocacy organizations and clinical centers, is collaborating to advance treatments for...
21:49 , Dec 2, 2016 |  BC Week In Review  |  Company News

Lilly, IntelGenx deal

Eli Lilly granted IntelGenx rights to U.S. Patent No. 6,943,166, which covers dosing of Lilly’s tadalafil. IntelGenx says the deal will allow it to commercialize its Tadalafil ED Versafilm in the U.S. before the expiration...
11:43 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

Tadalafil PharmFilm regulatory update

MonoSol submitted an NDA to FDA for Tadalafil PharmFilm to treat erectile dysfunction (ED). The product is a film formulation of tadalafil, a phosphodiesterase-5 (PDE-5) inhibitor. MonoSol Rx LLC , Warren, N.J.  Product: Tadalafil PharmFilm ...
23:38 , Nov 21, 2016 |  BioCentury  |  Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
07:00 , Oct 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and mouse studies identified a dual PDE-5 / HDAC inhibitor that could help treat AD. Chemical synthesis and in vitro testing of molecules that combined structural features of known...